Singapore Becomes First Country to Reach WHO's Highest Rating for Medical Device Regulation

On March 10, 2026, the World Health Organization announced that Singapore's Health Sciences Authority (HSA) achieved Maturity Level 4 (ML4) — the highest classification in WHO's Global Benchmarking Tool for medical device regulation.

Singapore is the first country in the world to reach this level for medical devices.

This isn't just a symbolic milestone. For medtech companies planning international market entry, it has real strategic implications.

What Is WHO Maturity Level 4?

WHO's Global Benchmarking Tool Plus for medical devices (GBT+MD) evaluates national regulatory authorities on a scale from ML1 (no formal system) to ML4 (advanced, with continuous improvement).

ML4 means:

• The regulatory system operates at an advanced performance level
• Continuous improvement mechanisms are embedded
• Safety, quality, and performance of devices are ensured throughout the entire lifecycle — from market authorization through post-market surveillance
• The authority can serve as a reference regulator for other countries

Only 32% of regulatory authorities worldwide can fully ensure that health products meet required safety and quality standards. Singapore is now the gold standard for medical devices.

Why This Matters for Medtech Companies

1. HSA Approval Carries More Weight Than Ever

HSA was already recognized as a reference authority by several ASEAN markets and beyond. With ML4, that credibility is now formally backed by WHO's highest endorsement.

What this means practically:

• Other regulators will increasingly rely on HSA decisions. Markets that accept reference authority approvals (Malaysia, Thailand, Philippines, and others) have even more reason to fast-track HSA-approved devices.
• HSA is positioning itself as a "WHO Listed Authority" for devices. HSA already holds WLA status for medicines (2023). Device WLA would make it a formal global reference point — alongside FDA, EMA, and TGA.

2. Singapore-First Strategy Gets Stronger

For companies choosing their market entry sequence, Singapore was already attractive:

• English-language submissions
• Clear timelines (30–270 working days depending on route)
• Reliance pathways that accept FDA/CE/TGA approvals
• Gateway to 700+ million people across ASEAN

Now add: WHO's top-rated regulatory system. Singapore approval becomes a stronger credential when approaching investors, partners, and subsequent regulators.

3. The ASEAN Ripple Effect

Singapore is a founding member of the ASEAN Medical Device Directive (AMDD) framework. As other ASEAN members develop their regulatory systems (many are at ML1–ML2), they increasingly rely on Singapore's assessments.

With ML4, HSA's influence in shaping ASEAN harmonization grows. Companies that enter Singapore first and build their ASEAN CSDT (Common Submission Dossier Template) around HSA requirements are positioning for the smoothest path across Southeast Asia.

Singapore's Regulatory Track Record

This ML4 for devices follows a pattern:

HSA also holds Stringent Regulatory Authority (SRA) status for high-risk in-vitro diagnostics. Singapore is building a complete regulatory ecosystem across all health product categories.

The Singapore Medtech Landscape

Singapore hosts approximately 200 medical device manufacturers producing everything from in-vitro diagnostics to Software as a Medical Device (SaMD). The country has invested heavily in medtech innovation, with major R&D hubs and a regulatory environment designed to balance safety with timely market access.

For foreign manufacturers, Singapore offers:

• No local clinical trial requirement for most devices (clinical evidence from other markets accepted)
• Authorized Representative (AR) system that handles the registration process
• Post-market surveillance that's structured but manageable
• Fee structure that's reasonable compared to FDA/EU (SGD 1,560–12,560 depending on route and class)

What Should Companies Do Now?

If you're planning APAC market entry:

1. Prioritize Singapore. The ML4 designation makes HSA approval an increasingly valuable credential for subsequent markets.
2. Use reliance pathways. If you have FDA clearance or CE marking, HSA's abridged evaluation route can get you approved in 90–180 working days.
3. Prepare the ASEAN CSDT. Build your submission in CSDT format from the start — it's reusable across ASEAN markets.
4. Monitor WLA developments. When HSA achieves WLA for devices (likely coming), more markets will formally accept HSA decisions.

If you're already in Singapore:

• This changes nothing about your regulatory obligations, but it strengthens the credibility of your HSA approval when entering new markets.

Classify Your Device for Singapore

Not sure how your device classifies under HSA's system? regMD's free classification tool gives you instant results across Singapore and 14 other jurisdictions — including the optimal market entry sequence.

For a complete regulatory strategy report with timelines, costs, and recognition pathways, get lifetime access for $99.

Source: WHO announcement, March 10, 2026